Pharvaris Reports Third Quarter Financial Results and Clinical Updates
Pharvaris N.V. (PHVS) reported its third-quarter financial results, highlighting a net loss of €47.4 million, an increase from the €37.1 million loss recorded in the same period last year. The company's earnings per share (EPS) for the quarter stood at -$0.67. As of September 30, 2026, Pharvaris reported cash and cash equivalents of €283 million, a slight decrease from the €292 million held as of December 31, 2025. Despite the widening net loss, the company continues to focus on its clinical pipeline, specifically regarding topline results for its Phase III study of Deucrictibant for the prophylactic treatment of Hereditary Angioedema (HAE).
Topics: cash position clinical trial results earnings report net loss